Pharming Group N.V annual operating expenses
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Operating Expenses Growth & History (PHAR)
Pharming Group N.V's operating expenses was $304.8M for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $304.8M | $34.4M | +12.71% |
| 2024 | 2024-12-31 | $270.4M | $44.9M | +19.93% |
| 2023 | 2023-12-31 | $225.5M | $55.7M | +32.78% |
| 2022 | 2022-12-31 | $169.8M | $5.7M | +3.45% |
| 2021 | 2021-12-31 | $164.2M | $51.8M | +46.08% |
| 2020 | 2020-12-31 | $112.4M | $15.2M | +15.60% |
| 2019 | 2019-12-31 | $97.2M | — | — |
Pharming Group N.V quarterly operating expenses
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $75.8M | $530,000 | +0.70% |
| Q1 2026 | 2026-03-31 | $71.1M | — | — |
| Q4 2025 | 2025-12-31 | $83.4M | — | — |
| Q3 2025 | 2025-09-30 | $74.5M | — | — |
| Q2 2025 | 2025-06-30 | $75.2M | — | — |
Pharming Group N.V operating expenses trends
Over the last five fiscal years, Pharming Group N.V's operating expenses increased from $112.4M to $304.8M, a change of $192.4M. The latest reported quarter, Q2 2026, shows $75.8M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...